A 2-step decision analytic model consisting of a decision tree-informed Markov structure was used to estimate lifetime outcomes in older patients with prostate cancer. The P-score reclassifies a ...
—A recent analysis showed that health concerns, rather than costs, influenced treatment strategies in commercially insured men with prostate cancer. Among men with newly diagnosed prostate cancer, ...
LOS ANGELES (KABC) -- Proton therapy to treat prostate cancer has been available in Southern California for nearly 35 years. It's less invasive and offers fewer side effects compared to conventional ...
Costs increased between 2010 and 2020 for follow-up diagnostic testing after PSA-based screening. (HealthDay News) — For patients with private insurance undergoing diagnostic testing after ...
Out-of-pocket costs for tests used to diagnose prostate cancer have increased in recent years, according to research published in Cancer. Researchers found that out-of-pocket costs for prostate biopsy ...
NEW YORK (Reuters Health) - The total cost burden of prostate cancer varies significantly by treatment type, according to a new report. "I would like this information to be used by clinicians to ...
2024 OCT 23 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating ...
Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.
Prostate-specific antigen (PSA) screening aims to identify men who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive (and expensive) ...
A new model that compares costs and outcomes of drugs used in the treatment of castrate-resistant prostate cancer has concluded that generic docetaxel and abiraterone (Zytiga) offer better value than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback